Clinical trial · Interventional
Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
NCT03121729CI-TRIAL-00032715ERASG1unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| enhanced recovery after surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- enhanced recovery after surgery
- description
- enhanced recovery after surgery includes: 1. Multimodal analgesia 2. Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet 3. Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early 4. Early activity 5. Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken
- interventionNames
- Procedure: enhanced recovery after surgery
Primary outcomes (1)
- measure
- occurrence rate of severe complications
- timeFrame
- 1 month
- description
- including death, anastomotic fistula, intra-abdominal hemorrhage, hemorrhage of digestive tract and complications need a reoperation
Secondary outcomes (33)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Requirements of informed consent and assent of participant, parent or legal guardian as applicable 2. Patients with gastric cancer scheduled for radical gastrectomy and between the age of 18 and 75 years old without considering sex 3. ASA physical status I-III 4. Participants can follow the drug doses and visit plan Exclusion Criteria: 1. Patients certified by a doctor that doesn't fit to participate in this study. 2. Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or their cardiac function \> II (NYHA) patients, patients received CABG recently, and patients with severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110mmHg). 3. Patients with gastric cancer with distant metastasis. 4. Patients with severe infection, respiratory dysfunction, coagulation disorders, severe liver and renal dysfunction (Child - Pugh≥ 10; creatinine clearance \< 25 ml/min). 5. Patients allergic to common drugs, such as opioids, non-steroidal drugs, cephalosporins, etc. 6. Patients with operations of gastrointestinal cancer and complicated abdominal operations. 7. Patients complicated by gastric cancer with complications such as hemorrhage, perforation, obstruction. 8. Patients with dyscrasia and severe malnutrition (albumin≤30g/L, weight loss in half a year\>10%, SGA classification C, BMI\<18, Hb\<70g/L). 9. Patients with metabolic complications caused by diabetes. 10. Patients can't finish enhanced recovery after surgery programs and have contraindications of enhanced recovery after surgery. 11. Pregnancy and lactation women, or have a pregnancy plan within a month after the test of the subjects (also including male participants). 12. Patients participated other subjects 3 months before this subject. 13. Sponsors or researchers directly involved in the testing or their family members.
References
Publications (0)
Data not yet available
No reference posted for this study.